Here are four things to know.
1. Between 2001 and 2014, two AmerisourceBergen subsidiaries — Oncology Supply Co. and the now shuttered Medical Initiatives — packaged millions of syringes in an unapproved facility, according to a from the U.S. Department of Justice.
2. The DOJ also said Medical Initiatives prepared syringes by transferring excess drugs from glass vials into the plastic syringes in an “unclean, unsterile environment,” according to the DOJ release. Prosecutors claim the wholesaler refrained from registering the facility with the FDA to avoid regulatory oversight.
3. AmerisourceBergen, which disclosed the deal with the DOJ in August, will pay $260 million in penalties.
4. The U.S. Attorney’s Office in Brooklyn, which brought the criminal charge, may also pursue civil claims against the wholesaler under the False Claims Act. AmerisourceBergen is free to contest claims for all criminal information to which it did not plead guilty in future legal matters.
More articles on supply chain:
Hurricane Maria stalls shipments of Baxter’s IV products: 4 things to know
US Army delivers 3-day fuel supply to Puerto Rican children’s hospital|
Millennials least likely to comply with recall notices, study finds
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.